Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 7, 2003

View Archived Issues

SBIR grant to fund investigation of Triapine's antiviral activity

BMS obtains license to Elan NanoCrystal technology

ViroPharma awarded SBIR grants to support biodefense effects

Avecia awarded anthrax vaccine contract by NIAID

Antiinflammatory effects of Ono-6126 in healthy volunteers

Potential benefits reported for the anticonvulsant vigabatrin in cocaine addiction

Improved lung function in asthmatics after treatment with roflumilast

Pregabalin in generalized anxiety disorder

New MMP inhibitors and their use reported by British Biotech and Serono researchers

Novel lipase inhibitors prepared and tested by Aventis scientists

Two series of antibacterial oxazolidinones with decreased MAO activity presented by AstraZeneca

Pharmacia (now Pfizer) claims new IKK-2 inhibitors for cancer and inflammation

Pfizer team identifies new glycogen phosphorylase inhibitors for diabetes and related disorders

New xanthine oxidase inhibitors described in Fuji Yakuhin patent

Actelion to acquire Axovan, obtaining rights to clazosentan

Barr to acquire Plan B emergency contraceptive

Chiron gains certain development and commercialization rights to Cubicin

Pivotal ocinaplon trial on hold pending additional safety information

Orion to withdraw German filing for Simdax and resubmit at later date

6-Aminouracil DNA polymerase IIIC inhibitors as new antibacterial agents

Hybrid antibacterial agents with dual oxazolidinone and quinolone properties

Chiron designs potent ketolide antibacterial agents

VIC-200603: a ramoplanin derivative with good local tolerability following systemic administration

Inhaled AWD-12-281 exerts potent bronchodilating effects in animal model of asthma

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...